A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator’s Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck

OBJECTIVES: In the CheckMate 141 trial (NCT02105636), nivolumab demonstrated survival, health-related quality of life, and healthcare resource utilization benefits vs single-agent therapy of investigator’s choice (IC) (methotrexate, docetaxel or cetuximab) in patients with platinum-refractory recurr...

Descripción completa

Detalles Bibliográficos
Autores principales: Cocks, Kim, Contente, Marta, Simpson, Sarah, DeRosa, Michael, Taylor, Fiona C., Shaw, James W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830425/
https://www.ncbi.nlm.nih.gov/pubmed/30972702
http://dx.doi.org/10.1007/s40273-019-00798-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830425/
https://www.ncbi.nlm.nih.gov/pubmed/30972702
http://dx.doi.org/10.1007/s40273-019-00798-1

Ejemplares similares